CD8A and cancer: Besides, the use of low doses of Doxorubicin to inhibit AKT-activated β-catenin in LSCs reportedly impedes immune checkpoint binding to the β-catenin promoter while mediating the synergistic activation of immune responses by extrinsic and intrinsic CD8+ cytotoxic lymphocyte (CD8+T cells), providing a novel strategy to overcome drug resistance and immune escape in cancer treatment [35] (Fig. 4).